JLE

European Journal of Dermatology

MENU

Use of recombinant C1 inhibitor in patients with resistant or frequent attacks of hereditary or acquired angioedema Volume 24, issue 1, January-February 2014

Figures


  • Figure 1

  • Figure 2

  • Figure 3

Tables

Authors
Department of Immunology,
Barts Health NHS Trust,
London E1 2ES, UK
* Reprints

Background: Conestat alfa (Ruconest, rhC1INH) is the first recombinant human C1 inhibitor protein (C1INH) for the treatment of acute attacks of hereditary angioedema (HAE). Objective: To assess clinical experience of the first 11 adult patients who received rhC1INH in clinical practice in the UK. Methods: Eleven patients (nine HAE type 1, one HAE type 2 and one acquired angioedema with C1 inhibitor deficiency) received between one and six, mostly self-administered, doses of rhC1INH for acute HAE attacks. They were asked to record their time to first response and complete resolution following the treatment. This cohort included our most severely affected and difficult to treat patients. Results: In most cases, time to first improvement following rhC1INH and complete resolution was recorded as comparable to their typical response to pdC1INH, although 4/11 patients reported that the time to first improvement was much quicker than their average pdC1INH response. Five of the 11 patients continued with rhC1INH as their preferred rescue treatment. Of those who chose not to continue the treatment, four reported a recurrence or early return of symptoms with rhC1INH. Conclusion: In our experience, rhC1INH is a beneficial treatment for patients with preference for a C1INH that is not plasma derived and it is suitable for home treatment. In some cases it demonstrates cost saving, especially for heavier patients who require higher doses. In some patients rhC1INH may result in faster resolution of symptoms. It may be associated with an early return of symptoms in patients with exceptionally frequent attacks.